Paper
0
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Authors
Stephen Johnston,Masakazu Toi
Joyce O’Shaughnessy,Priya Rastogi,Mario Campone,Patrick Neven,Chiun‐Sheng Huang,Jens Huober,Georgina Jaliffe,İrfan Çiçin,Sara Tolaney,Matthew Goetz,Hope Rugo,Elżbieta Senkus,Laura Testa,Lucia Mastro,Chikako Shimizu,Ran Wei,Ashwin Shahir,Marı́a Muñoz,Belén Antonio,Valérie André,Nadia Harbeck,Miguel Martín
+22 authors
,Bélen AntonioJournal
Published
Dec 6, 2022
Show more
Save
Tip0
TipSave
Abstract
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.